Curis 2025 Q3 Earnings Beats Expectations with 71.2% Earnings Improvement

Curis (CRIS) reported fiscal 2025 Q3 earnings on November 7, 2025, . .

Revenue

Total revenue rose 8.4% to $3.18 million in Q3 2025, . , driven by its core drug development programs.

Earnings/Net Income

, . The company also reduced its net loss to $7.73 million, . This marked a significant step toward financial stability, though losses remain a key concern.

Price Action

, reflecting investor optimism about improved financial performance and clinical progress. However, , .

Post-Earnings Price Action Review

. Over the past three years, , . Backtesting across Q3, Q2, , even amid market volatility. , reinforcing the strategy’s reliability for investors seeking to leverage Curis’s performance.

CEO Commentary

, CLL, and AML clinical trials, . , .

Guidance

. . , 2025, .

Additional News

1. M&A Activity, managed by O...

2. IPO Launch: Curis Lifesciences, a separate entity, , 2025, .

3. Clinical Updates, , 2025.